Stimulation of the gonadotropic axis by the neuropeptide Y receptor Y1 antagonist/Y4 agonist 1229U91 in the male rat

Neuroendocrinology

Volumn 71, Issue 1, 2000, Pages 2-7

  Raposinho, Paula D ^a   Broqua, Pierre ^a,b   Hayward, Amanda ^b   Akinsanya, Karen ^b   Galyean, Robert ^c   Schteingart, Claudio ^c   Junien, Jean Louis ^b   Aubert, Michel L ^a,d  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b Ferring Research Institute Ltd   (United Kingdom)

^c Ferring Pharmaceuticals AS   (Denmark)

^d Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

Author keywords

Gonadotropin releasing hormone; Gonadotropins; Neuropeptide Y; Neuropeptide Y receptors

Indexed keywords

CORTICOSTERONE; FOLLITROPIN; GR 231118; GROWTH HORMONE; LUTEINIZING HORMONE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; RECEPTOR SUBTYPE; THYROTROPIN;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CORTICOSTERONE RELEASE; FOLLITROPIN RELEASE; GONADOTROPIN RELEASE; LUTEINIZING HORMONE RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THYROTROPIN RELEASE;

EID: 0033970517     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054514     Document Type: Article

References (29)

1. Tatemoto K, Carlquist M, Mutt V: Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982;285:417-418.
2. Danger JM, Tonon MC, Jenks BG, Saint-Pierre S, Martel JC, Fasolo A, Breton B, Quirion R, Pelletier G, Vaudry H: Neuropeptide Y: Localization in the central nervous system and neuroendocrine functions. Fundam Clin Pharmacol 1990;4:307-340.
3. Stanley BG, Leibowitz SF: Neuropeptide Y injected in the paraventricular nucleus: A powerful stimulant of feeding behaviour. Proc Natl Acad Sci USA 1985;82:3940-3943.
4. Kalra SP, Crowley WR: Norepinephrine-like effects of neuropeptide Y in the rat. Life Sci 1984;35:1173-1176.
5. McDonald JK, Lumpkin MD, DePaolo LV: Neuropeptide Y suppresses pulsatile secretion of luteinizing hormone in ovariectomized rats: Possible site of action. Endocrinology 1989; 125:186-191.
6. Kalra SP: Mandatory neuropeptide-steroid signaling for the preovulatory luteinizing hormone-releasing hormone discharge. Endocr Rev 1993;14:507-538.
7. Catzeflis C, Pierroz DD, Rohner-Jeanrenaud F, Rivier JE, Sizonenko PC, Aubert ML: Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993; 132:224-234.
8. Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML: Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in adult male rats. Endocrinology 1996; 137:3-12.
9. Blomqvist AG, Herzog H: Y-receptor subtypes - how many more? Trends Neurosci 1997;20: 294-298.
10. Gehlert DR: Multiple receptors for the pancreatic polypeptide (PP-fold) family: Physiological implications. Proc Soc Exp Biol Med 1998;218:7-22.
11. Wyss P, Stricker-Krongrad A, Brunner L, Miller A, Crossthwaite A, Whitebread S, Criscione L: The pharmacology of neuropeptide Y (NPY) receptor-mediated feeding in rats characterizes better Y5 than Y1, but not Y2 or Y4 subtypes. Regul Pept 1998;75-76:363-371.
12. Kalra SP, Fuentes M, Fournier A, Parker SL, Crowley WR: Involvement of the Y-1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats. Endocrinology 1992;130:3323-3330.
13. Raposinho PD, Broqua P, Pierroz DD, Hayward A, Dumont Y, Quirion R, Junien JL, Aubert ML: Evidence that the inhibition of LH secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominently mediated by the NPY-Y5 receptor subtype. Endocrinology 1999;140:4046-4055.
14. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA: Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther 1995; 275:136-142.
15. Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN: Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol 1998;125:549-555.
16. Daniels AJ, Matthews JE, Slepetis RJ, Jansen M, Viveros OH, Tadepalli A, Harrington W, Heyer D, Landavazo A, Leban JJ, Spaltenstein A: High-affinity neuropeptide Y antagonists. Proc Natl Acad Sci USA 1995;92:9067-9071.
17. Rüeger H, Schmidlin T, Rigollier P, Yamaguchi Y, Tintelnot-Blomley M, Schilling W, Criscione L, Mah R: Receptor Antagonists. Novartis AG Patent WO 97/20823. Example No. 53, p 91, 1997.
18. Bitran M, Daniels AJ, Boric MP: 1229U91, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstriction effect of neuropeptide Y in the hamster microcirculation. Eur J Pharmacol 1997;319:43-47.
19. 1 receptor antagonist, 1229U91: Blockade of neuropeptide Y-induced and physiological food intake. Endocrinology 1996;137:3177-3182.
20. Ishihara A, Tanaka T, Kanatani A, Fukami M, Ihara M, Fukuroda T: A potent neuropeptide Y antagonist, 1229U91, suppressed spontaneous food intake in Zucker fatty rats. Am J Physiol 1998;274:R1500-R1504.
21. Gehlert DR, Schober DA, Beavers L, Gadski R, Hoffmann JA, Smiley DL, Chance RE, Lundell I, Larhammar D: Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor. Mol Pharmacol 1996;50:112-118.
22. Parker EM, Babij CK, Balasubramanian A, Burrier RE, Guzzi M, Hamud F, Mukhopadhyay G, Rudinski MS, Tao Z, Tice M, Xia L, Mullins DE, Salisbury BG: GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y-1 receptor antagonists and neuropeptide Y Y-4 receptor agonists. Eur J Pharmacol 1998;349:97-105.
23. 4) receptor. Peptide 1998;19:537-542.
24. Daniels AJ, Heyer D, Landavazo A, Leban JJ, Spaltenstein A: Patent Cooperation Treaty (PCT) Publ. WO94/00486, 1994.
25. Broqua P, Aebi AC, Jiang GC, Stalewski J, Semple G, Akinsanya K, Haigh R, Riviere P, Rivier J, Aubert ML, Junien JL: Pharmacological profile of FE200486, a potent, water-soluble and long-acting GnRH antagonist (abstract 18). 5th Int Symp on GnRH Analogues in Cancer and Human Reproduction, Geneva 1999.
26. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
27. Kalra SP, Crowley WR: Differential effects of pancreatic polypeptide on luteinizing hormone release in female rats. Neuroendocrinology 1984;38:511-513.
28. Kalra PS, Jain MR, Pu S, Kalra SP: NPY and GnRH: A role of Y4 and coexpresscd GABA (abstract). 5th Int NPY Meeting. Grand Cayman Island 1999, p 30.
29. Jain MR, Pu S, Kalra PS, Kalra SP: Evidence that stimulation of two modalities of pituitary luteinizing hormone release in ovarian steroid-primed rats may involve neuropeptide Y Y1 and Y4 receptors. Endocrinology 1999;140: 5171-5177.